Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO July 21, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 21, 2026
Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported July 21, 2026
Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial July 15, 2026
Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer July 15, 2026
Global Ph 3 study of HBI-8000 plus nivolumab met the PFS primary endpoint in frontline patients with advanced melanoma July 15, 2026
Publication in The JCO Demonstrating DeltEx DRI Doubles PFS in Newly Diagnosed Glioblastoma July 15, 2026
Results from ELEVATE study of postoperative adjuvant ensartinib in stage IB–IIIB (T3N2M0) ALK-positive NSCLC published in NEJM July 15, 2026
Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced July 15, 2026
Primary Results Announced from Ph 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs July 15, 2026
Updated Survival Data Presented from Ph 3 Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses July 15, 2026
Clinical results of Ph 1b/2 trial of ifebemtinib + garsorasib in 1L KRASG12C-mutant NSCLC published in The Lancet Respiratory Medicine July 15, 2026
Global Data for Pumitamig Shows Encouraging Efficacy in NSCLC Patients in ROSETTA Lung-02 Trial July 15, 2026
Orphan Drug Designation Request submitted to the FDA for GDT Cell Therapy Targeting Glioblastoma July 15, 2026
ESMO GI 2026: BOT+BAL Data Showing 33% Three-Year OS in Refractory MSS Metastatic CRC Without Active Liver Metastases July 15, 2026
Positive Ph 3 Results for Epcoritamab + Lenalidomide in R/R DLBCL Patients Demonstrated Statistically Significant PFS Improvement July 7, 2026
Positive Interim Ph 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability of PAS-004, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Announced July 7, 2026
Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma published in Journal of Clinical Oncology (JCO) July 7, 2026
Ph 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease July 7, 2026
Positive Ph 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control, Reported July 7, 2026
Divarasib shows superiority in head-to-head Ph 3 trial against sotorasib or adagrasib in NSCLC July 7, 2026
ESMO GI 2026: Ph 1/2 Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer Presented July 7, 2026
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors June 30, 2026
